Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3662ce5995dada5ea3d9873552592af0 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2020-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8944453e3be8f276b692d7991f5f55ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77206b532d499079a2bd2f693769f75a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60a947f5ab4151fa08189de1270f0b9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc18873dfab13746f2d6b0a3fb9ec4b1 |
publicationDate |
2020-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2020103293-A |
titleOfInvention |
RSV-specific antibody and functional part thereof |
abstract |
PROBLEM TO BE SOLVED: To provide an antibody capable of specifically binding to RSV and a functional equivalent thereof, and a means and a method for producing them. SOLUTION: The respiratory syncytial virus can specifically bind to a. A heavy chain variable region CDR1 sequence comprising the sequence NYIIN or the sequence DYIIN; b. A heavy chain variable region CDR2 sequence comprising the sequence GIIPVLGTVHYAPKFQG or the sequence GIIPVLGTVHYGPKFQG, and c. A heavy chain variable region CDR3 sequence comprising the sequence ETALVVSTTYLPHYFDN or the sequence ETALVVSTTYRPHYFDN; d. A light chain variable region CDR1 sequence comprising a sequence that is at least 85% identical to the sequence QASQDIVNYLN, and e. A light chain variable region CDR2 sequence comprising the sequence VASNLE, f. A synthetic or recombinant antibody which may comprise a light chain variable region CDR3 sequence comprising the sequence QQYDNLP. [Selection diagram] None |
priorityDate |
2014-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |